Please ensure Javascript is enabled for purposes of website accessibility

3 Marijuana Stocks That Could Be Millionaire Makers

By Sushree Mohanty – Updated Sep 7, 2021 at 10:18AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Outstanding quarterly results yet again prove these three pot stocks have the potential to turn your investment into millions.

It's no longer a surprise when U.S. cannabis companies report an outstanding quarter. The marijuana boom that started amid the coronavirus pandemic lifted both revenue and earnings for pot companies, and the continuing expansion of state marijuana legalization has kept the momentum going. Though the federal ban on marijuana poses some difficulties, that is not stopping these companies from expanding.

Illinois-based Green Thumb Industries (GTBIF -1.43%) and Cresco Labs (CRLBF -3.31%) and Florida-based Trulieve Cannabis (TCNNF 0.19%) all recently reported another strong quarter. Let me tell you why I think these three cannabis stocks are millionaire makers. 

a marijuana leaf surrounded by American dollar bills.

Image source: Getty Images.

1. Green Thumb Industries

Green Thumb grew revenue 85% year over year to $222 million in the second quarter ended June 30. The company attributed this growth to its 58 open and operating retail stores. Most revenue came in from key markets like Illinois and Pennsylvania, where it operates nine and 16 retail stores, respectively.

Illinois, a relatively new recreational market (which legalized adult use in January 2020), has generated close to $753 million in sales through July. The state is on its way to breaking last year's record of $1 billion in sales for the full year. Illinois being Green Thumb's home state is an added advantage. The company also entered the Virginia cannabis market by acquiring 100% of cannabis grower and producer Dharma Pharmaceuticals. In July, Virginia made recreational cannabis legal, but retail sales won't begin until Jan. 1, 2024. 

The revenue growth also brought in fourth consecutive quarter of profits -- this time reaching $22 million, versus a net loss of $13 million in the year-ago period.  It ended the quarter with cash and cash equivalents of $359.2 million and $198 million in total debt outstanding. With rising revenue and profits, it is in good financial standing to clear its debts. It holds licenses for 111 retail stores in 14 U.S. markets.

2. Cresco Labs

Cresco has also benefited from the growing Illinois market. Its second quarter, ended June 30, saw a whopping 123% year-over-year increase in revenue to $210 million. The company's retail revenue, generated from 33 stores during the quarter, grew to $101 million, up 157% year over year. Much of the credit goes to its Sunnyside retail platform. Cresco has 11 Sunnyside stores in Illinois.

The company reported adjusted earnings before interest, taxes, depreciation, and amortization, or EBITDA, of $45 million and net income of $2.7 million for the quarter, compared with a loss of $41 million in Q2 2020. Though Cresco doesn't have a large national presence yet, it is in a stable financial position to continue expanding as more states legalize marijuana. It ended the second quarter with cash and cash equivalents of $131 million and term loan debt (net of issuance costs) of $189.4 million.

3. Trulieve Cannabis

Trulieve has been consistently performing well in the last few quarters. Most of the credit goes to sales from its home state of Florida, where it operates 85 stores. In its recent second quarter, its total revenue grew 78% year over year to $215 million. This higher revenue contributed to another quarter of profits, which also marked its 14th consecutive quarter of profitability. It recorded adjusted EBITDA of $95 million, a 55% jump from the prior-year quarter, while net profits of $41 million showed a 16% year-over-year increase.

The company's acquisition of Arizona-based Harvest Health & Recreation in May was the highlight of the industry this year. Once complete, this acquisition will allow Trulieve access to markets in Arizona, Pennsylvania, and Maryland, with a total store count of 140 and 3 million square feet of cultivation capacity in the U.S.

The acquisition will bring a strong footing in the national market. Management expects the combined company could generate about $1.2 billion in revenue and $461 million in adjusted EBITDA in 2021. Harvest Health reported an outstanding second quarter (which ended June 30) with $102 million in revenue and adjusted EBITDA of $11.3 million.

The only thing Trulieve needs to change now is its reliance on the medical cannabis market, especially in Florida. The recreational segment is a hot opportunity in the U.S., with ever more states legalizing adult-use marijuana. Trulieve should concentrate more now on developing quality recreational products, in particular derivatives like vapes, edibles, and beverages. These high-margin products can boost the company's profits.

Financially, the company is in a sound position. It ended the second quarter with cash and cash equivalents of $289 million and net debt of $118 million at the end of Q2.

Are they millionaire-maker stocks?

All three companies have already reached half a billion dollars in revenue each in the first half of 2021, and each is also profitable. With marijuana sales rising, I wouldn't be surprised if each one manages to generate $1 billion or more revenue by year-end. That revenue growth will boost profits as well. So imagine the growth when federal legalization happens. Wall Street analysts have huge expectations for these three stocks. In the past three years, Green Thumb's, Trulieve's, and Cresco's shares have gained 182%, 165%, and 95%, respectively, while the industry benchmark, the Horizons Marijuana Life Sciences ETF, has fallen 48%.

GTBIF Chart

GTBIF data by YCharts

Analysts see upside of 163%, 97%, and 60% for Trulieve, Cresco, and Green Thumb in the next 12 months.

The question is, can they make you a millionaire? I believe they can. But note that investment is a long-term game. Each of these stocks is selling for less than $30 today; if that price were to reach $100 in the next 10 years, buying 10,000 shares of each of these pot stocks now could easily turn your investment into millions. Based on the current trading price, investors would need to buy $264,000, $295,000, and $96,000 worth, respectively, of Trulieve, Green Thumb, and Cresco to turn that investment into seven figures if and when the stocks reach $100 each.

Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Cresco Labs Inc., Green Thumb Industries, and Trulieve Cannabis Corp. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Green Thumb Industries Stock Quote
Green Thumb Industries
GTBIF
$13.06 (-1.43%) $0.19
Trulieve Cannabis Corp. Stock Quote
Trulieve Cannabis Corp.
TCNNF
$13.05 (0.19%) $0.03
Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
CRLBF
$3.21 (-3.31%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.